LifeStance Health releases data on treatment-resistant depression outcomes

LifeStance Health released updated findings regarding clinical outcomes for patients suffering from treatment-resistant depression. The data evaluates the efficacy of esketamine and transcranial magnetic stimulation (TMS) as therapeutic interventions within their clinical network.

According to the report, patients receiving these specialized treatments demonstrated statistically significant reductions in depressive symptoms. The study serves to quantify the patient response rate to non-traditional psychiatric interventions outside of standard oral medication protocols.

This release follows a correction issued by the company regarding previously disclosed metrics. As mental health providers increasingly adopt interventional psychiatry, such data points provide visibility into the effectiveness of these therapies in community-based outpatient settings.

LifeStance continues to manage a wide network of psychiatrists and therapists. The company tracks these outcomes to standardize care protocols for patients who have not responded to conventional antidepressant treatments.